Company Announcements

hVIVO plc

("hVIVO" or the "Company")

Director's Dealings

London, UK, 3 October 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, application has been made to AIM for the admission of 25,349 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of his letter of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Winschel had entered into a binding commitment to purchase £4,000 of hVIVO plc New Ordinary Shares per quarter.

The New Ordinary Shares represent Mr Winschel's investment for the quarter ended September 2019.  On 3 October 2019, Mr Winschel invested in an additional 25,349 ordinary shares, at a price of 15.78 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of Ordinary Shares with voting rights in issue will be 83,235,251 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 9 October 2019.  Following Admission, Mr Winschel will be interested in a total of 154,548 ordinary shares of 5.0p in the Company, representing 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

For further information please contact:

Notes to Editors:

hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.  Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.